Literature DB >> 10618106

Recovery and analysis of human immunodeficiency virus type 1 (HIV) RNA sequences from plasma samples with low HIV RNA levels.

J Niubò1, W Li, K Henry, A Erice.   

Abstract

Amplification of human immunodeficiency virus type 1 (HIV) reverse transcriptase (RT) and protease (PT) sequences from plasma is difficult when HIV RNA levels are low, and it usually cannot be accomplished in samples with <1,000 HIV RNA copies/ml. Because the RNA extraction step is critical for the success of subsequent amplifications and sequence analyses, two RNA extraction methods were compared to study plasma samples with low HIV RNA levels. Forty-four plasma samples containing <500 HIV RNA copies/ml in a branched-DNA (bDNA) assay (Quantiplex HIV RNA assay version 2.0 [Chiron Corp., Emeryville, Calif.]) were studied. RNA was extracted by using two commercial kits (QIAamp Viral RNA kit [Qiagen, Hilden, Germany] and NucliSens kit [Organon Teknika, Boxtel, The Netherlands]). Fragments (1,144 bp) encompassing HIV PT and RT sequences were amplified by nested PCRs. Amplified products were sequenced by using a commercial kit (Applied Biosystems). HIV RNA was recovered from a total of 21 plasma samples, including 20 samples after extraction by the NucliSens method, and 8 samples after extraction by the QIAamp method (P < 0.05). Mean HIV RNA levels in these samples, measured by an ultrasensitive bDNA assay (Quantiplex HIV RNA assay version 3.0; Chiron Corp., Emeryville, Calif.), were 848 copies/ml (median, 666; range, 154 to 2,606 copies/ml). Analysis of RT and PT sequences in five samples demonstrated an average of 3.8 and 2.4 resistance mutations in these regions, respectively. The NucliSens RNA extraction kit is a valuable method for obtaining HIV RNA for genotypic studies from plasma fractions of individuals with low HIV RNA levels.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10618106      PMCID: PMC88714          DOI: 10.1128/JCM.38.1.309-312.2000

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  15 in total

1.  Isolation of HIV-1 RNA from plasma: evaluation of eight different extraction methods.

Authors:  C Verhofstede; K Fransen; D Marissens; R Verhelst; G van der Groen; S Lauwers; G Zissis; J Plum
Journal:  J Virol Methods       Date:  1996-07       Impact factor: 2.014

2.  CD4-cell count in HIV-1-infected individuals remaining viraemic with highly active antiretroviral therapy (HAART). Swiss HIV Cohort Study.

Authors:  D Kaufmann; G Pantaleo; P Sudre; A Telenti
Journal:  Lancet       Date:  1998-03-07       Impact factor: 79.321

3.  A branched DNA signal amplification assay for quantification of nucleic acid targets below 100 molecules/ml.

Authors:  M L Collins; B Irvine; D Tyner; E Fine; C Zayati; C Chang; T Horn; D Ahle; J Detmer; L P Shen; J Kolberg; S Bushnell; M S Urdea; D D Ho
Journal:  Nucleic Acids Res       Date:  1997-08-01       Impact factor: 16.971

4.  Complete nucleotide sequence of the AIDS virus, HTLV-III.

Authors:  L Ratner; W Haseltine; R Patarca; K J Livak; B Starcich; S F Josephs; E R Doran; J A Rafalski; E A Whitehorn; K Baumeister
Journal:  Nature       Date:  1985 Jan 24-30       Impact factor: 49.962

5.  Human immunodeficiency virus replication and genotypic resistance in blood and lymph nodes after a year of potent antiretroviral therapy.

Authors:  H F Günthard; J K Wong; C C Ignacio; J C Guatelli; N L Riggs; D V Havlir; D D Richman
Journal:  J Virol       Date:  1998-03       Impact factor: 5.103

6.  Reduction of HIV-1 in blood and lymph nodes following potent antiretroviral therapy and the virologic correlates of treatment failure.

Authors:  J K Wong; H F Günthard; D V Havlir; Z Q Zhang; A T Haase; C C Ignacio; S Kwok; E Emini; D D Richman
Journal:  Proc Natl Acad Sci U S A       Date:  1997-11-11       Impact factor: 11.205

7.  Impaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitors.

Authors:  G Croteau; L Doyon; D Thibeault; G McKercher; L Pilote; D Lamarre
Journal:  J Virol       Date:  1997-02       Impact factor: 5.103

8.  Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions.

Authors:  G M Lucas; R E Chaisson; R D Moore
Journal:  Ann Intern Med       Date:  1999-07-20       Impact factor: 25.391

9.  Rapid and precise quantification of HIV-1 RNA in plasma using a branched DNA signal amplification assay.

Authors:  C Pachl; J A Todd; D G Kern; P J Sheridan; S J Fong; M Stempien; B Hoo; D Besemer; T Yeghiazarian; B Irvine
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1995-04-15

Review 10.  Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society--USA Panel.

Authors:  M S Hirsch; B Conway; R T D'Aquila; V A Johnson; F Brun-Vézinet; B Clotet; L M Demeter; S M Hammer; D M Jacobsen; D R Kuritzkes; C Loveday; J W Mellors; S Vella; D D Richman
Journal:  JAMA       Date:  1998-06-24       Impact factor: 56.272

View more
  4 in total

1.  Detection of herpes simplex virus DNA in genital and dermal specimens by LightCycler PCR after extraction using the IsoQuick, MagNA Pure, and BioRobot 9604 methods.

Authors:  M J Espy; P N Rys; A D Wold; J R Uhl; L M Sloan; G D Jenkins; D M Ilstrup; F R Cockerill; R Patel; J E Rosenblatt; T F Smith
Journal:  J Clin Microbiol       Date:  2001-06       Impact factor: 5.948

2.  Comparative study of two methods for RNA extraction prior to detection of resistance to human immunodeficiency virus type 1 with the line probe assay.

Authors:  Jose María Eiros; Cristina Labayru; Beatriz Hernández; Raúl Ortiz De Lejarazu; Antonio Rodríguez Torres
Journal:  J Clin Microbiol       Date:  2002-06       Impact factor: 5.948

3.  Comparison of the NucliSens Basic kit (Nucleic Acid Sequence-Based Amplification) and the Argene Biosoft Enterovirus Consensus Reverse Transcription-PCR assays for rapid detection of enterovirus RNA in clinical specimens.

Authors:  Marie L Landry; Robin Garner; David Ferguson
Journal:  J Clin Microbiol       Date:  2003-11       Impact factor: 5.948

4.  A Guide to HIV-1 Reverse Transcriptase and Protease Sequencing for Drug Resistance Studies.

Authors:  Robert W Shafer; Kathryn Dupnik; Mark A Winters; Susan H Eshleman
Journal:  HIV Seq Compend       Date:  2001
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.